Origin Therapeutics Launches to Fund Emerging Psychedelics Companies
VANCOUVER, British Columbia, July 21, 2021 (GLOBE NEWSWIRE) — Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”), an actively managed investment issuer focused on making equity investments in psychedelics-related companies, is pleased to announce its launch.
The Company is focused on providing retail investors with exposure to a portfolio of diverse private companies in the psychedelics sector that they would otherwise be unable to participate in the growth of.
“There is a tremendous amount of innovation taking place in the psychedelics sector,” said Origin Therapeutics CEO Alexander Somjen. “Investors want to get in on it – but for many, it is only possible to access companies that are already publicly traded, which means that a lot of that initial opportunity to participate in the earliest stages of growth has passed.”
Origin Therapeutics plans to invest in a diverse range of psychedelic companies that encompass different areas of growth in the industry. This could include early-stage drug development companies, clinics, and other ancillary companies that help to push the industry forward, such as those companies focused on education, marketing, and building awareness around the psychedelics industry.
“We believe this industry has the potential to revolutionize a crucial area of healthcare,” Somjen said. “There is an increased interest in mental health, and psychedelics are a promising untapped resource that we have just scratched the surface of.”
According to a 2017 report from Our World in Data, around one in seven people globally (11-18%) have one or more mental health or substance use disorders. Data Bridge Market Research estimates that the psychedelics industry will grow to $6.9 billion by 2027.
About Origin Therapeutics
Origin Therapeutics Holdings Inc. (CSE: ORIG Proposed) (the “Company” or “Origin Therapeutics”) is an actively managed investment issuer focused on making equity investments in psychedelics-related companies to provide investors with diverse exposure to the sector. The Company, led by a team of industry experts, leverages its management expertise, professional network, and due diligence process to identify leading and emerging global companies that are innovating in the sector and are supported by science. Learn more: https://originpsychedelics.com/
For Further Information:
Alexander Somjen
Chief Executive Officer and Director
Origin Therapeutics Holdings Inc
www.originpsychedelics.com
info@originpsychedelics.com
For media inquiries, please contact: Brittany@Exvera.com
Forward-Looking Information and Statements
Certain statements in this news release related to the Company are forward-looking statements and are prospective in nature. Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events, and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward- looking statements. These statements generally can be identified by the use of forward-looking words such as “may”, “should”, “could”, “intend”, “estimate”, “plan”, “anticipate”, “expect”, “believe” or “continue”, or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the closing of the Offering, the intended use of proceeds of the Offering, the filing of the Prospectus and the obtaining of receipts for the Prospectus. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks inherent in the Company’s business in general; (iii) that the proceeds of the Offering may need to be used for purposes other than as set out in this news release and other factors beyond the control of the Company. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward- looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by applicable law, the Company does not intend to update these forward-looking statements.
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
